Since joining Kirkland & Ellis, Jingwen has been involved in the following:
- Beijing Airdoc Technology Co., Ltd. (HKSE: 2251), a global leader and pioneer in providing AI-empowered retina-based early detection, auxiliary diagnosis and health risk assessment solutions, on its US$215 million global offering and listing on The Stock Exchange of Hong Kong Limited
- The joint sponsors and underwriters on the US$400 million global offering and listing of Keymed Biosciences Inc. (HKSE: 2162), a biotechnology company focuses on the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas, on The Stock Exchange of Hong Kong Limited on July 8, 2021
- Zhaoke Ophthalmology Limited (HKSE: 6622), a spin-off of Lee’s Pharmaceutical Holdings Limited (HKSE: 0950), on its US$270 million global offering and listing on the Hong Kong Exchanges and Clearing Limited on April 29, 2021. Goldman Sachs (Asia) L.L.C. and Jefferies Hong Kong Limited were joint sponsors and joint representatives for this IPO
- EDDA Healthcare and Technology Holding Limited, a pioneer in the field of intelligent robotic solutions for precision surgery, on the successful completion of a US$150 million financing round. Softbank Vision Fund 2 led this investment round with participation from OrbiMed and 3W Fund
Prior to joining Kirkland & Ellis, Jingwen has been involved in the following:
- Yum China Holdings, Inc. (HKEX:9987, NYSE:YUMC) in connection with its secondary listing on the Main Board of The Stock Exchange of Hong Kong. The offering raised net proceeds of approximately HK$17 billion (US$2.2 billion). Yum China is the largest restaurant company in China with flagship brands including KFC and Pizza Hut, as well as emerging brands such as Little Sheep, Huang Ji Huang, COFFii & JOY, East Dawning, Taco Bell, and Lavazza
- Ocumension Therapeutics (HKEX: 1477), in its HK$1.42 billion (approximately US$182.5 million) initial public offering (IPO) on the Main Board of the Stock Exchange of Hong Kong. Ocumension Therapeutics, which started its business in 2017, is an ophthalmic pharmaceutical platform company dedicated to identifying, developing, and commercializing first or best-in-class ophthalmic therapies
- Kangji Medical Holdings Limited (HKEX:9997), in connection with its US$404 million (HK$3.13 billion) initial public offering on the Main Board of the Stock Exchange of Hong Kong. Established in 2004, Kangji Medical is the largest domestic minimally invasive surgical instruments and accessories platform in China
- China International Capital Corporation Hong Kong Securities Limited, Merrill Lynch Far East Limited, CMB International Capital Limited, Fosun Hani Securities Limited and Citigroup Global Markets Asia Limited as joint sponsors; China International Capital Corporation Hong Kong Securities Limited, Merrill Lynch (Asia Pacific) Limited, BOCI Asia Limited, UBS AG Hong Kong Branch, CMB International Capital Limited, Fosun Hani Securities Limited and Citigroup Global Markets Asia Limited as the joint global coordinators; and several other underwriters in connection with the global offering and listing of H-shares of Shanghai Henlius Biotech, Inc. This listing is also a dual-level spin-off from Hong Kong-listed Fosun International and A+H-listed Fosun Pharma. Shanghai Henlius Biotech, Inc. is a leading biopharmaceutical company in China. Proceeds: US$397.4 million
- Huatai Financial Holdings (Hong Kong) Limited, Credit Suisse (Hong Kong) Limited as joint sponsors; Huatai Financial Holdings (Hong Kong) Limited, Credit Suisse (Hong Kong) Limited, Citigroup Global Markets Asia Limited, CLSA Limited as the joint global coordinators; and several other underwriters in connection with the global offering and listing of H-shares of China Youran Dairy Group Limited (HKSE: 9858) . Youran Dairy is a leading company in China’s dairy farming industry
- China Xinhua Education Group Limited (HKSE: 2779) in connection with its initial public offering listed on the Main Board of The Stock Exchange of Hong Kong Limited. According to Frost & Sullivan data, in terms of the number of full-time students enrolled in higher education courses, the group has become the largest higher education group in the Yangtze River Delta
- China East Education Holdings Limited (HKSE: 667) in connection with its initial public offering listed on the Main Board of The Stock Exchange of Hong Kong Limited. China East Education is a pioneer in providing vocational training education in China
- Contel Technology Company Limited (HKSE: 1912) in connection with its initial public offering listed on the Main Board of The Stock Exchange of Hong Kong Limited. Contel Technology is a well-established fabless semiconductor application solutions provider
- Palace Banquet Holdings Limited (HKSE: 1703) in connection with its initial public offering listed on the Main Board of The Stock Exchange of Hong Kong Limited. It is an investment holding company mainly engaged in the operation of restaurants. The company operates Chinese restaurants under the brands of Huangfu and Huangyuan
